All patients with T2D with either diabetic renal disease OR heart failure OR CV disease OR five-year CV disease risk > 15% should ideally be on metformin, SGLT2i (and/or GLP1RA) regardless of their glycaemic control or other OHA.

Formal Recommendations

Recommendation & Evidence

Recommendation StrengthNone

Evidence LevelNone

PICO Question

无

Population

People with type 2 diabetes and diabetic kidney disease, heart failure, cardiovascular disease, or 5-year cardiovascular risk >15%

Intervention

Metformin plus an SGLT2 inhibitor and/or GLP-1 receptor agonist regardless of glycemic control or other oral agents

Comparison

Not explicitly stated

Outcome

Reduction of cardiovascular and kidney risk

Evidence Information

Evidence No.-

Evidence-

Evidence LevelNone

Recommendation StrengthNone

Statement TypeFormal Recommendations

Guideline Information

Guideline NameSamoa MOH National Diabetes Guidelines

Guideline No.2-2024-035E

AuthorAlec Ekeroma

Guideline TypeGuideline

Year2024

OrganizationMinistry of Health Samoa

RegionOceania

CountrySamoa

Conflict of InterestNo

DOI无

Target Population所有糖尿病患者（包括1型糖尿病、2型糖尿病、妊娠期糖尿病、儿童及青少年），特别是萨摩亚及太平洋人群，包括高危人群（超重/肥胖、有家族史、既往糖尿病史等）

Journal无

Recommendation Strength Methodology无

Evidence Level Methodology无

Other Information

Living GuidelineNo

Rapid AdviceNo

UpdatedNo

Recommendation Count0

Reference Count50

Guideline TopicComprehensive

CategoriesSodium–glucose cotransporter 2 (SGLT2) inhibitors, Cardiovascular disease, Glycaemic targets and glucose-lowering treatment in people with chronic kidney disease

Created At2026-07-28 17:47:18

Updated At2026-07-28 17:47:18